BioAdaptives (BioAdaptives) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BioAdaptives is: No Data: Cannot be evaluated.

Competitive Comparison of BioAdaptives's Risk Assessment

For the Packaged Foods subindustry, BioAdaptives's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioAdaptives's Risk Assessment Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Risk Assessment falls into.

BioAdaptives (OTCPK:BDPT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BioAdaptives Risk Assessment Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAdaptives (BioAdaptives) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128

Website

https://www.shopbioadaptives.com

BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.

Executives

Richard Chiang	other: Previous Officer and Director	460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling	director	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc.	10 percent owner	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling	director, officer: Pres, CEO, Secretary, CFO	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128